Liquidia Corporation Share Price & Technical Analysis
LQDA · $60.98 (-1.60%)
Healthcare / Drug Manufacturers - Specialty & Generic
$60.98
-1.60%
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease…
Price chart
Seasonality
May has 3 positive and 1 negative years (last 5 years shown)
56% return in May, 9% avg return in past 3 year May month.
77% return in 2026, 63% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 23% | -27% | 23% | 2% | 56% | – | – | – | – | – | – | – | 77% |
| 25 | 20% | 11% | -4% | -5% | 6% | -25% | 51% | 50% | -22% | 10% | 20% | 7% | 119% |
| 24 | 8% | 11% | 4% | -17% | 0% | -18% | -2% | -21% | 5% | 9% | 5% | 3% | -12% |
| 23 | 3% | 15% | -9% | -3% | 21% | -4% | -3% | -10% | -9% | 3% | 11% | 67% | 82% |
| 22 | 16% | 14% | 11% | -25% | -24% | 5% | 11% | 18% | 6% | -11% | 0% | 25% | 47% |
Monthly return % by calendar month · historical pattern, not a forecast
Neutral · Strong · Overbought
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil which is in phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). In addition, the company offers PRINT technology which allows to engineer and manufacture uniform drug particles with precise control over the size, three-dimensional geometric shape, and chemical composition of the particles. It has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD; Vectura; The University of North Carolina at Chapel Hill; GlaxoSmithKline; Alcon Inc; and promotion Agreement with Sandoz. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$4.77B
P/E ratio
315.35
52W high
$62.30
52W low
$11.85
Volume
9,57,199
Beta
0.42
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Liquidia Corporation share price today?
- Liquidia Corporation (LQDA) last traded around $60.98 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does LQDA have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for LQDA. Download the app for real-time alerts.
- How can I analyze Liquidia Corporation stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.